Cabio Biotech Wuhan Co Ltd
SSE:688089
Intrinsic Value
Cabio Biotech Wuhan Co Ltd is a China-based company principally engaged in biotechnology business. [ Read More ]
The intrinsic value of one Cabio Biotech Wuhan Co Ltd stock under the Base Case scenario is 16.46 CNY. Compared to the current market price of 17.08 CNY, Cabio Biotech Wuhan Co Ltd is Overvalued by 4%.
Valuation Backtest
Cabio Biotech Wuhan Co Ltd
Run backtest to discover the historical profit from buying and selling Cabio Biotech Wuhan Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cabio Biotech Wuhan Co Ltd
| Current Assets | 730.9m |
| Cash & Short-Term Investments | 276.3m |
| Receivables | 273.2m |
| Other Current Assets | 181.5m |
| Non-Current Assets | 824.8m |
| Long-Term Investments | 173.9m |
| PP&E | 572.1m |
| Intangibles | 36m |
| Other Non-Current Assets | 42.9m |
| Current Liabilities | 81.6m |
| Accounts Payable | 45.9m |
| Accrued Liabilities | 12.3m |
| Short-Term Debt | 10m |
| Other Current Liabilities | 13.3m |
| Non-Current Liabilities | 16.6m |
| Long-Term Debt | 1.8m |
| Other Non-Current Liabilities | 14.8m |
Earnings Waterfall
Cabio Biotech Wuhan Co Ltd
|
Revenue
|
485m
CNY
|
|
Cost of Revenue
|
-297.1m
CNY
|
|
Gross Profit
|
187.9m
CNY
|
|
Operating Expenses
|
-156.7m
CNY
|
|
Operating Income
|
31.2m
CNY
|
|
Other Expenses
|
15.7m
CNY
|
|
Net Income
|
46.9m
CNY
|
Free Cash Flow Analysis
Cabio Biotech Wuhan Co Ltd
Profitability Score
Profitability Due Diligence
Cabio Biotech Wuhan Co Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Cabio Biotech Wuhan Co Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Cabio Biotech Wuhan Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Cabio Biotech Wuhan Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Cabio Biotech Wuhan Co Ltd
According to Wall Street analysts, the average 1-year price target for Cabio Biotech Wuhan Co Ltd is 17.34 CNY with a low forecast of 17.17 CNY and a high forecast of 17.85 CNY.
Shareholder Return
Price
Cabio Biotech Wuhan Co Ltd
| Average Annual Return | 4.92% |
| Standard Deviation of Annual Returns | 36.54% |
| Max Drawdown | -85% |
| Market Capitalization | 2.9B CNY |
| Shares Outstanding | 168 309 120 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cabio Biotech Wuhan Co Ltd is a China-based company principally engaged in biotechnology business. The Company is mainly engaged in the research and development, production and sales of polyunsaturated fatty acids arachidonic acid (ARA), algal oil docosahexaenoic acid (DHA) and sialic acid (SA), and natural beta-carotene products. Its products are mainly used in infant formula food, dietary supplements, nutritional health food and formula food for special medical purposes. The Company integrates industrial strain-oriented optimization technology, fermentation fine control technology, and efficient separation, purification and preparation technology, and provides nutrient products and innovative solutions for customers in the global nutrition and health field through sustainable microbial synthesis and manufacturing methods. The Company mainly conducts its business in domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Cabio Biotech Wuhan Co Ltd stock under the Base Case scenario is 16.46 CNY.
Compared to the current market price of 17.08 CNY, Cabio Biotech Wuhan Co Ltd is Overvalued by 4%.
You don't have any saved screeners yet
